NLRC5 (NLR Family CARD Domain Containing 5) is the largest member of the NOD-like receptor (NLR) family, comprising 1,866 amino acids with a molecular weight of approximately 204 kDa. Originally identified as a transcriptional regulator of major histocompatibility complex (MHC) class I genes, NLRC5 has emerged as a critical player in innate and adaptive immune responses. [@meinnel2021][@kobayashi2021] While direct evidence linking NLRC5 to neurodegenerative diseases remains limited, its role in immune regulation, inflammasome signaling, and MHC class I expression provides important context for understanding neuroinflammatory processes in Alzheimer's disease (AD) and Parkinson's disease (PD).
The NLR family encompasses a diverse group of intracellular pattern recognition receptors (PRRs) that sense microbial products, cellular stress, and damage signals. [@benko2010] Among the more than 20 NLR proteins in humans, NLRC5 stands out for its unique structural features and specialized functions in immune regulation.
:: infobox .infobox-protein
| Protein Name | NLRC5 |
| Gene | NLRC5 |
| UniProt | Q86TI2 |
| Molecular Weight | ~204 kDa |
| Length | 1,866 amino acids |
| Subcellular Localization | Cytoplasm, Nucleus |
| Protein Family | NLR family, NOD-like receptor family |
| Chromosome | 16q13 |
::
NLRC5 (NLR family CARD domain containing 5) represents the largest member of the NOD-like receptor (NLR) family, comprising 1,866 amino acids with a molecular weight of approximately 204 kDa. Originally identified as a transcriptional regulator of major histocompatibility complex (MHC) class I genes, NLRC5 has emerged as a critical regulator of innate and adaptive immunity, inflammasome assembly, and cellular stress responses. [@meinnel2021] The protein is uniquely distinguished among NLR family members by possessing an N-terminal caspase recruitment domain (CARD) instead of the pyrin domain (PYD) found in most other NLR proteins, which enables direct interaction with downstream signaling intermediates.
Beyond its well-established immunological functions, recent research has begun to illuminate potential roles for NLRC5 in the nervous system, including modulation of neuroinflammation, microglial activation, and possibly neurodegenerative disease pathogenesis. The NLR family as a whole has been increasingly implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions, making NLRC5 an intriguing target for investigation. [@eisen2022]
The NLRC5 gene is ubiquitously expressed with highest levels in immune cells (lymphocytes, monocytes, macrophages) and various tissues including lung, liver, and kidney. Brain expression has been documented in neurons, astrocytes, and microglia, though its precise functions in the central nervous system remain an area of active research.
| Attribute | Value |
|---|---|
| Protein Name | NLRC5 |
| Gene Symbol | NLRC5 |
| Gene | NLRC5 |
| UniProt ID | Q86TI2 |
| Molecular Weight | ~204 kDa |
| Length | 1,866 amino acids |
| Chromosomal Location | 16q13 |
| Expression | Broad - immune cells, brain (microglia, neurons) |
| Protein Name | NLRC5 (NLR Family CARD Domain Containing 5) |
| Gene | NLRC5 |
| UniProt ID | Q86TI2 |
| Molecular Weight | ~204 kDa (1,866 amino acids) |
| Subcellular Localization | Cytoplasm, Nucleus |
| Protein Family | NLR family, NOD-like receptor family |
| Chromosome | 16p13.13 |
| Expression | High in immune cells, moderate in brain |
NLRC5 possesses a distinctive domain organization that differentiates it from other NLR family members:
N-Terminal CARD Domain (residues 1-92): Unlike most NLR proteins that contain a pyrin domain (PYD), NLRC5 harbors an N-terminal caspase recruitment domain (CARD). This unique feature enables NLRC5 to potentially interact directly with caspase adaptors and signaling molecules. [@lupfer2013] The CARD domain facilitates protein-protein interactions essential for downstream signaling cascades.
NACHT Domain (residues 219-579): The central NACHT domain (named after NAIP, CIITA, HET-E, and TP1) serves as the ATPase core of the protein. This domain is critical for NLRC5 self-oligomerization and activation. ATP binding induces conformational changes that enable higher-order complex formation.
LRR Domain (residues 750-1037): The C-terminal leucine-rich repeat (LRR) domain functions as a sensor module, potentially recognizing pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). The LRR domain also participates in autoregulation by maintaining the protein in an inactive state under basal conditions.
Unlike NLRP3 or NLRC4, which form canonical inflammasomes, NLRC5 functions primarily as a transcriptional regulator. The presence of the CARD domain instead of a PYD domain is a key structural distinction that determines its signaling mechanism.
NLRC5 serves as the master transcriptional regulator of MHC class I genes, controlling the expression of classical MHC class I molecules (HLA-A, HLA-B, HLA-C) as well as non-classical MHC class I molecules (HLA-E, HLA-F, HLA-G). [@meinnel2021][@goto2020]
Mechanism of Action:
This function is critical for:
NLRC5 participates in multiple innate immune pathways:
Type I Interferon Response: NLRC5 positively regulates IFN-beta production during viral infections by enhancing the expression of key interferon-stimulated genes.
NF-κB Signaling: NLRC5 modulates NF-κB activation pathways, influencing the expression of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β.
Antiviral Defense: NLRC5 expression is induced by interferon stimulation, and the protein contributes to the cellular antiviral response.
While NLRC5 can form inflammasome-like complexes under certain conditions, its inflammasome function is less characterized than NLRP3 or NLRC4. [@broz2016] Studies suggest NLRC5 may:
Through its regulation of MHC class I expression, NLRC5 profoundly impacts adaptive immune responses: [@strowig2012]
NLRC5 exhibits broad expression across multiple tissue types:
| Tissue/Cell Type | Expression Level |
|---|---|
| Lymphocytes | High |
| Macrophages | High |
| Dendritic Cells | High |
| Spleen | Moderate |
| Lung | Moderate |
| Liver | Moderate |
| Brain | Low to Moderate |
| Microglia | Detectable |
| Neurons | Low |
In resting cells, NLRC5 localizes predominantly to the cytoplasm. Upon activation, a fraction of NLRC5 translocates to the nucleus where it exerts its transcriptional regulatory functions. This dual localization enables NLRC5 to serve as both a signaling molecule and a transcription factor.
While direct evidence for NLRC5 involvement in Alzheimer's disease or Parkinson's disease is limited, several lines of evidence suggest potential connections through the broader NLR family and immune regulatory functions.
The NLR family has been increasingly implicated in neurodegenerative processes. [@cheng2023][@liu2022]
NLRP3 Inflammasome in AD/PD:
NOD-like Receptor Signaling:
MHC Class I in the Brain:
MHC class I molecules are expressed in neurons and glia, where they participate in:
Aberrant MHC class I expression has been implicated in:
Neuroinflammation and Adaptive Immunity:
The role of adaptive immunity in neurodegeneration is increasingly recognized:
Microglial NLRC5:
Microglia express NLRC5 and respond to immune challenges:
While no NLRC5-targeted therapies exist currently, several approaches could be explored:
Immunomodulation: Modulating NLRC5 activity might influence neuroinflammation through effects on microglial function and MHC class I expression.
T Cell Modulation: Since CD8+ T cells contribute to neurodegeneration, regulating MHC class I expression could alter T cell-mediated effects.
Viral Model Connections: Given NLRC5's role in antiviral immunity, understanding its function in the brain could illuminate how viral infections might trigger or exacerbate neurodegeneration.
| Interactor | Interaction Type | Functional Consequence |
|---|---|---|
| CIITA | Co-activator | MHC class I transcription |
| Caspase-1 | Potential binding | Inflammasome signaling |
| IKKβ | Modulation | NF-κB pathway regulation |
| STAT1 | Cooperation | Interferon response |
| Beta-2 microglobulin | Regulation | MHC class I assembly |
Autoimmune Diseases:
Infectious Diseases:
Cancer:
Key questions remain regarding NLRC5 in neurodegeneration:
Direct assessment of NLRC5 expression in AD and PD brain tissue
Functional studies of NLRC5 in microglia and neurons
Understanding how NLRC5-mediated MHC class I regulation affects neuronal health
Potential contributions to age-related neuroinflammation
NLRC5 possesses a distinctive domain organization that distinguishes it from other NLR family members:
N-terminal CARD Domain (residues 1-65): Unlike most NLR proteins that contain a PYD, NLRC5 harbors a CARD domain that enables direct interaction with downstream signaling molecules including the NF-κB pathway components. This domain mediates homophilic CARD-CARD interactions with adaptor proteins and is crucial for signal transduction. [@kobayashi2021]
NACHT Domain (residues 426-607): The central nucleotide-binding domain (also called NBD or NACHT) mediates oligomerization and ATP/d GTP-dependent conformational changes required for inflammasome assembly and signaling. The NACHT domain contains Walker A (P-loop) and Walker B motifs essential for nucleotide binding and hydrolysis. [@wang2021]
LRR Domain (Leucine-Rich Repeat, residues 784-1035): The C-terminal LRR domain is involved in ligand sensing and autorepression. In the resting state, the LRR domain interacts with the NACHT domain to maintain NLRC5 in an inactive conformation. Ligand binding or cellular stress triggers conformational rearrangement leading to activation.
Fish Domain (domain found in NLR family, residues 608-783): A helical domain connecting the NACHT and LRR domains, involved in protein-protein interactions.
| Feature | NLRC5 | NLRP3 | NOD1 | NOD2 |
|---|---|---|---|---|
| N-terminal domain | CARD | PYD | CARD | CARD |
| Inflammasome forming | Yes | Yes | No | Yes |
| MHC regulation | Yes | No | No | No |
| Size (aa) | 1,866 | 742 | 785 | 1,040 |
Meinnel et al., NLRC5: master regulator of MHC class I genes (2021)
Kobayashi & van Loo, NLRC5 in immunity and inflammation (2021)
Lupfer et al., NLRC5 functions in MHC class I and II genes (2013)
Zhou et al., NLRP3 inflammasome in neurodegenerative diseases (2020)
Broz & Dixit, Inflammasomes: mechanism and regulation (2016)
Liu et al., NOD-like receptor signaling in PD (2022)
NLRC5 serves as the master transcriptional regulator of MHC class I genes, a function discovered through systematic screening approaches: [@meinnel2021]
Direct transcriptional activation: NLRC5 binds to promoter regions of MHC class I genes (HLA-A, HLA-B, HLA-C, β2-microglobulin) through direct association with CIITA (Class II Transactivator), the master regulator of MHC class II expression
Chromatin remodeling: NLRC5 recruits chromatin-modifying complexes to MHC class I gene promoters, enhancing transcriptional accessibility
Cooperative regulation: Works synergistically with CIITA and other transcription factors (NF-κB, IRF1) to ensure appropriate MHC class I expression
Tissue-specific control: Important for MHC class I expression in tissues with low basal expression, including neurons and some epithelial cells
NLRC5 participates in multiple innate immune pathways: [@kuenzel2021][@trans2020]
NLRC5 modulates type I interferon (IFN-α/β) responses: [@onshi2021]
NLRC5 interacts with the NF-κB pathway: [@liu2022]
While not as well-characterized as NLRP3 or AIM2 inflammasomes, NLRC5 can form inflammasome complexes: [@hashimoto2022]
Recent studies reveal NLRC5 involvement in autophagy: [@li2020]
NLRC5 is expressed in the central nervous system: [@chen2021][@kim2021]
Emerging evidence links NLRC5 to Alzheimer's disease pathogenesis through multiple mechanisms:
NLRC5 may contribute to Parkinson's disease pathogenesis:
| Partner | Interaction Type | Functional Consequence |
|---|---|---|
| CIITA | Co-activation | MHC class I transcription |
| NF-κB subunits | Direct binding | Inflammatory signaling |
| Pro-caspase-1 | CARD-CARD | Inflammasome assembly |
| ASC | Protein binding | Inflammasome formation |
| RIPK2 | Direct binding | NOD2 signaling cross-talk |
| IKK complex | Direct binding | NF-κB activation |
| Approach | Status | Target | Indication |
|---|---|---|---|
| Small molecule inhibitors | Research | NACHT domain | Inflammatory diseases |
| Peptide antagonists | Research | CARD domain | Autoimmune conditions |
| Gene therapy | Preclinical | NLRC5 expression | Cancer immunotherapy |
| CRISPR targeting | Research | NLRC5 gene | Various |
While most drug development has focused on NLRP3, lessons from NLRC5 research inform broader strategies:
Existing drugs that may affect NLRC5:
Structural studies: Cryo-EM structures reveal NLRC5 activation mechanism and inflammasome assembly. [@hashimoto2022]
Brain function: Single-cell studies identify NLRC5 in microglia and its role in neuroinflammation. [@kim2021]
Therapeutic potential: NLRC5 emerges as potential target for cancer immunotherapy, with ongoing studies. [@yu2022]
Post-translational regulation: New findings on phosphorylation and ubiquitination of NLRC5. [@zhang2022]
Disease genetics: NLRC5 variants associated with autoimmune and infectious disease susceptibility. [@cai2021]
Cross-talk with NLRP3: Studies reveal coordination between NLRC5 and NLRP3 inflammasomes. [@rathinam2022]
Autophagy connections: New links between NLRC5 and selective autophagy pathways. [@li2020]
The NLRC5 gene shows conservation across vertebrates, with orthologs identified in mammals, birds, and fish. Evolutionary analysis reveals that the CARD domain-containing NLRC5 lineage diverged from the PYD-containing NLRP subfamily early in vertebrate evolution. This structural diversification likely reflects distinct functional requirements for NLR proteins in different immune pathways.
| Species | NLRC5 Ortholog | Key Features |
|---|---|---|
| Human | NLRC5 | Full-length, CARD-containing |
| Mouse | Nlrc5 | 97% similarity in NACHT/LRR |
| Zebrafish | nlrc5-like | Truncated N-terminus |
| Chicken | NLRC5 | Conserved domain structure |
Understanding NLRC5 in the context of better-characterized NLRs provides insight into its unique functions.
Knockout mice have provided crucial insights into NLRC5 function:
MHC Class I Deficiency: Nlrc5-/- mice exhibit 50-80% reduction in MHC class I surface expression on splenocytes and fibroblasts
Impaired CD8+ T Cell Responses: Reduced cytotoxic T cell responses to viral infections and tumors
NK Cell Dysregulation: Altered NK cell activation due to MHC class I recognition changes
Viral Susceptibility: Increased susceptibility to various viral infections
Tissue-specific knockout models have revealed:
Given its critical role in antiviral immunity, NLRC5's function in viral infections provides important context for understanding neuroimmune interactions.
Viral infections of the central nervous system trigger neuroinflammation:
Single nucleotide polymorphisms (SNPs) in the NLRC5 gene have been associated with:
Understanding NLRC5 requires specialized approaches:
While not currently used clinically, NLRC5 could potentially serve as:
NLRC5 represents a unique member of the NLR family with distinct structural features and specialized functions. As the master regulator of MHC class I genes, it plays essential roles in both innate and adaptive immunity. While direct evidence for NLRC5 involvement in neurodegenerative diseases is limited, its functions in immune regulation, inflammasome signaling, and MHC class I expression provide important context for understanding neuroinflammatory processes. The broader NLR family, particularly NLRP3, has established roles in AD and PD pathogenesis, suggesting that further investigation of NLRC5 in neurodegeneration is warranted. Understanding NLRC5's functions in microglia, neurons, and infiltrating immune cells may reveal novel therapeutic approaches for modulating neuroinflammation in neurodegenerative conditions.